JACKSON CENTER, PA – January 31, 2023 – Halberd Corporation (OTC: HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd’s patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine. Read more
Over the course of the past months, Halberd Corporation (OTCMKTS:HALB) has been one of the companies to have done considerable research work in the field of healthcare and has also made some significant breakthroughs.
The company announced this morning that the animal testing collaboration that it was going to undertake at Mississippi State University was going to be centered on Halbder’s nasal spray meant for alleviating the effects of Traumatic Brain Injury. It should however be noted that the patent for the product is still pending. The product in question is meant to be administered right after a brain injury of that nature is suffered by anybody.
However, at the same time, it is also necessary to note that the animal testing work is going to take place over the course of the next several months and will be overseen by Dr. Russell Carr of the College of Veterinary Medicine at the university.
On the other hand, it is also necessary for investors to note that the company has also managed to secure the necessary funding for the purpose of this study. That had been secured after Halberd had managed to demonstrate that its process could eradicate all the known antigens associated with head trauma during in-vitro testing.
The Chief Technology Officer of the company Dr. Mitchell S Felder spoke about the latest development as well. He noted that everyone at the company had been impressed with the protocols that had been put in place for the purpose of traumatic head injury in animals at the Mississippi State University. He went on to state that the reason why the nasal spray from Halberd was different was the fact that it could be administered to the patient right after he actually suffers the injury. It could be a good idea to keep an eye on the Halberd stock today.